Antiinflammation effect of human placental multipotent mesenchymal stromal cells is mediated by prostaglandin E2 via a myeloid differentiation primary response gene 88-dependent pathway

Anesthesiology

Volumn 117, Issue 3, 2012, Pages 568-579

  Chen, Chie Pein ^a   Tsai, Pei Shan ^b   Huang, Chun Jen ^c,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; I KAPPA B ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROTEIN MD 2; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CONTACT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MACROPHAGE ACTIVATION; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PLACENTA; PLACENTAL MULTIPOTENT MESENCHYMAL STROMAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

ANIMALS; CELL COMMUNICATION; CELLS, CULTURED; DINOPROSTONE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MESENCHYMAL STROMAL CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPOTENT STEM CELLS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PLACENTA; PREGNANCY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865585292     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31826150a9     Document Type: Article

References (37)

1. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 1996; 77:110-7
2. Nussler AK, Billiar TR: Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993; 54: 171-8
3. Hammond RA, Hannon R, Frean SP, Armstrong SJ, Flower RJ, Bryant CE: Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Am J Vet Res 1999; 60:426-31
4. Christman JW, Lancaster LH, Blackwell TS: Nuclear factor kappa B: A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24:1131-8
5. Kristof AS, Marks-Konczalik J, Moss J: Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 2001; 276:8445-52
6. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E: Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-KB. J Immunol 2004; 172: 2522-9
7. Yang H, Young DW, Gusovsky F, Chow JC: Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 2000; 275:20861-6
8. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995; 9:726-35
9. Janssens S, Beyaert R: A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27:474-82
10. Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S: Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol 2000; 12:113-7
11. Barry FP, Murphy JM: Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36:568-84
12. Le Blanc K: Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5:485-9
13. Rasmusson I, Ringden O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305:33-41
14. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR: T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12:47-57
15. Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, Qian H, Zhang X: Isolation of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells. Cell Biol Int 2006; 30:681-7
16. Chen CP, Liu SH, Huang JP, Aplin JD, Wu YH, Chen PC, Hu CS, Ko CC, Lee MY, Chen CY: Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats. Hum Reprod 2009; 24:154-65
17. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, Yen BL: Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 2006; 24:2466-77
18. Lee MY, Huang JP, Chen YY, Aplin JD, Wu YH, Chen CY, Chen PC, Chen CP: Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on in-tegrin "5/31. PLoS One 2009; 4:e6913
19. + channel. Anesth Analg 2006; 102:1739-44
20. Tsai PS, Chen CC, Tsai PS, Yang LC, Huang WY, Huang CJ: Heme oxygenase 1, nuclear factor E2-related factor 2, and nuclear factor KB are involved in hemin inhibition of type 2 cationic amino acid transporter expression and L-Arginine transport in stimulated macrophages. ANESTHESIOLOGY 2006; 105:1201-10
21. Park GY, Le S, Park KH, Le CT, Kim YW, Han SK, Shim YS, Yoo CG: Anti-inflammatory effect of adenovirus-mediated I"Ba overexpression in respiratory epithelial cells. Eur Re-spir J 2001; 18:801-9
22. Németh ZH, Deitch EA, Lu Q, Szab ó C, Hask ó G: NHE blockade inhibits chemokine production and NF-kappaB activation in immunostimulated endothelial cells. Am J Physiol Cell Physiol 2002; 283:C396-403
23. Nareika A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y: Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NF-KB transcriptional activities. Am J Physiol Endocrinol Metab 2005; 289:E534-42
24. Rosenfeld Y, Papo N, Shai Y: Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem 2006; 281:1636-43
25. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN: Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002; 169: 5209-16
26. Lee IT, Lee CW, Tung WH, Wang SW, Lin CC, Shu JC, Yang CM: Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol 2010; 176:1671-84
27. Harvey K, Dzierzak E: Cell-cell contact and anatomical compatibility in stromal cell-mediated HSC support during development. Stem Cells 2004; 22:253-8
28. Tripathi S, Bruch D, Kittur DS: Ginger extract inhibits LPS induced macrophage activation and function. BMC Complement Altern Med 2008; 8:1
29. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent re-programming of host macrophages to increase their interleu-kin-10 production. Nat Med 2009; 15:42-9
30. Moreno C, Merino J, Vazquez B, Ramírez N, Echeverría A, Pastor F, Sanchez-Ibarrola A: Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression. Scand J Immunol 2004; 59:553-8
31. StavitskyAB: The innate immune response to infection, toxins and trauma evolved into networks of interactive, defensive, reparative, regulatory, injurious and pathogenic pathways. Mol Immunol 2007; 44:2787-99
32. Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Ka-washima Y, Koyama T, Ohwada S, Morishita Y: Effects of a dual inhibitor of tumor necrosis factor-a and interleukin-1 on lipopolysaccharide-induced lung injury in rats: Involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 2001; 29:628-34
33. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol 2002; 23:144-50
34. Xu XJ, Reichner JS, Mastrofrancesco B, Henry WL Jr., Albina JE: Prostaglandin E2 suppresses lipopolysaccharide-stimu-lated IFN-beta production. J Immunol 2008; 180:2125-31
35. Tchetina EV, Di Battista JA, Zukor DJ, Antoniou J, Poole AR: Prostaglandin PGE2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: This involves a decrease in expression of proinflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy. Arthritis Res Ther 2007; 9:R75
36. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-3
37. Opal SM: New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int J Antimicrob Agents 2010; 36 Suppl 2:S70-3